INM Stock Overview
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
InMed Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.35 |
52 Week High | US$2.08 |
52 Week Low | US$0.29 |
Beta | 0.46 |
1 Month Change | -19.31% |
3 Month Change | -10.61% |
1 Year Change | -70.10% |
3 Year Change | -99.58% |
5 Year Change | -99.90% |
Change since IPO | -99.84% |
Recent News & Updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02InMed's INM-755 CBN cream did not introduce any delay in normal wound healing
Jan 08Shareholder Returns
INM | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -4.6% | 1.2% | 0.4% |
1Y | -70.1% | 25.8% | 28.8% |
Return vs Industry: INM underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.
Return vs Market: INM underperformed the US Market which returned 29.5% over the past year.
Price Volatility
INM volatility | |
---|---|
INM Average Weekly Movement | 10.2% |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INM's share price has been volatile over the past 3 months.
Volatility Over Time: INM's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1981 | 13 | Eric Adams | https://www.inmedpharma.com |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products.
InMed Pharmaceuticals Inc. Fundamentals Summary
INM fundamental statistics | |
---|---|
Market cap | US$2.10m |
Earnings (TTM) | -US$6.35m |
Revenue (TTM) | US$5.49m |
0.4x
P/S Ratio-0.3x
P/E RatioIs INM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INM income statement (TTM) | |
---|---|
Revenue | US$5.49m |
Cost of Revenue | US$3.38m |
Gross Profit | US$2.11m |
Other Expenses | US$8.46m |
Earnings | -US$6.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.05 |
Gross Margin | 38.42% |
Net Profit Margin | -115.75% |
Debt/Equity Ratio | 0% |
How did INM perform over the long term?
See historical performance and comparison